DE69522827T2 - Fibrinogen receptor antagonisten mit substituierten b-aminosäurenestern und diese enthaltende pharmazeutische präparate - Google Patents

Fibrinogen receptor antagonisten mit substituierten b-aminosäurenestern und diese enthaltende pharmazeutische präparate

Info

Publication number
DE69522827T2
DE69522827T2 DE69522827T DE69522827T DE69522827T2 DE 69522827 T2 DE69522827 T2 DE 69522827T2 DE 69522827 T DE69522827 T DE 69522827T DE 69522827 T DE69522827 T DE 69522827T DE 69522827 T2 DE69522827 T2 DE 69522827T2
Authority
DE
Germany
Prior art keywords
substituted
amino acid
acid esters
receptor antagonists
pharmaceutical preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69522827T
Other languages
English (en)
Other versions
DE69522827D1 (de
Inventor
Yoshio Hayashi
Takeo Harada
Jun Katada
Akira Tachiki
Takeo Okazaki
Yoshimi Satoh
Hiroshi Miyazaki
Tohru Asari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Steel Corp
Original Assignee
Nippon Steel Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Steel Corp filed Critical Nippon Steel Corp
Publication of DE69522827D1 publication Critical patent/DE69522827D1/de
Application granted granted Critical
Publication of DE69522827T2 publication Critical patent/DE69522827T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69522827T 1994-12-28 1995-12-28 Fibrinogen receptor antagonisten mit substituierten b-aminosäurenestern und diese enthaltende pharmazeutische präparate Expired - Fee Related DE69522827T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP32898094 1994-12-28
JP25284195 1995-09-29
JP34174695A JP3874438B2 (ja) 1994-12-28 1995-12-27 置換β−アミノ酸残基を有するフィブリノーゲン受容体拮抗物質およびそれを有効成分とする医薬製剤
PCT/JP1995/002763 WO1996020172A1 (en) 1994-12-28 1995-12-28 FIBRINOGEN RECEPTOR ANTAGONISTS HAVING SUBSTITUTED β-AMINO ACID RESIDUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME

Publications (2)

Publication Number Publication Date
DE69522827D1 DE69522827D1 (de) 2001-10-25
DE69522827T2 true DE69522827T2 (de) 2002-04-11

Family

ID=27334161

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69522827T Expired - Fee Related DE69522827T2 (de) 1994-12-28 1995-12-28 Fibrinogen receptor antagonisten mit substituierten b-aminosäurenestern und diese enthaltende pharmazeutische präparate

Country Status (10)

Country Link
EP (1) EP0800516B1 (de)
JP (1) JP3874438B2 (de)
KR (1) KR100222391B1 (de)
AT (1) ATE205829T1 (de)
AU (1) AU692656B2 (de)
CA (1) CA2208682C (de)
DE (1) DE69522827T2 (de)
ES (1) ES2164168T3 (de)
TW (1) TW442469B (de)
WO (1) WO1996020172A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3874455B2 (ja) * 1996-06-27 2007-01-31 新日本製鐵株式会社 フィブリノーゲン受容体拮抗物質およびそれを有効成分とする医薬製剤
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
JP5617799B2 (ja) 2010-12-07 2014-11-05 信越化学工業株式会社 化学増幅レジスト材料及びパターン形成方法
KR101975897B1 (ko) 2019-02-12 2019-05-07 주식회사 에스브이티 기밀성이 강화된 볼 밸브
KR20200098358A (ko) 2019-04-16 2020-08-20 주식회사 에스브이티 이중의 씰링부재가 마련되어 기밀성이 강화된 볼 밸브

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2037153A1 (en) * 1990-03-09 1991-09-10 Leo Alig Acetic acid derivatives

Also Published As

Publication number Publication date
KR100222391B1 (ko) 1999-10-01
JPH09151175A (ja) 1997-06-10
DE69522827D1 (de) 2001-10-25
TW442469B (en) 2001-06-23
CA2208682A1 (en) 1996-07-04
ATE205829T1 (de) 2001-10-15
WO1996020172A1 (en) 1996-07-04
JP3874438B2 (ja) 2007-01-31
AU4356796A (en) 1996-07-19
CA2208682C (en) 2002-08-06
AU692656B2 (en) 1998-06-11
EP0800516B1 (de) 2001-09-19
ES2164168T3 (es) 2002-02-16
EP0800516A1 (de) 1997-10-15

Similar Documents

Publication Publication Date Title
FI872864A0 (fi) Menetelmä farmaseuttisesti aktiivisten bentsimidatsolijohdannaisten valmistamiseksi
SE8300736D0 (sv) Novel pharmacologically active compounds
ATE239726T1 (de) Verschmolzene benzazepinderivate und diese enthaltende pharmazeutische zubereitungen
EA200200119A1 (ru) β-КАРБОЛИНОВЫЕ ЛЕКАРСТВЕННЫЕ ПРОДУКТЫ
NO942952D0 (no) 11-benzaldoksin-17 ater, fremgangsmåte for deres fremstilling samt legemiddel inneholdende slike
ES2062610T3 (es) Compuesto diarilico anti-ateroesclerotico.
SE8804628D0 (sv) New compounds
DE69522827T2 (de) Fibrinogen receptor antagonisten mit substituierten b-aminosäurenestern und diese enthaltende pharmazeutische präparate
YU47338B (sh) Novo jedinjenje 4-fluoro-2-// (4-metoksi-2-piridinil)metil-/sulfinil/- 1h-benzimidazol i postupak za njegovo dobijanje
ATE38151T1 (de) Bestaendige 5-adenosyl-l-methionin-salze enthaltende, pharmazeutische zusammensetzungen fuer orale anwendung.
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
EP0535250A4 (en) Novel compounds and use thereof as medicine
GEP20002271B (en) Bicyclic Tachykinins Antagonists, Pharmaceutical Composition on Its Basis and Their Use
NO950177D0 (no) Farmakologisk aktive erivater
ATE260672T1 (de) Pharmazeutische lysin enthaltende polypeptid- zusammensetzungen und verfahren zu deren verwendung
EA200101157A1 (ru) 14β-H-СТЕРОЛЫ, СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И ПРИМЕНЕНИЕ ЭТИХ ПРОИЗВОДНЫХ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ, РЕГУЛИРУЮЩИХ МЕЙОЗ
DE69011692T2 (de) Therapeutische mittel.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee